PrabotulinumtoxinA · ~1:1 unit ratio to Botox · precise, lower-spread · FDA 2019 (Jeuveau).
AbobotulinumtoxinA · ~2.5:1-3:1 unit ratio to Botox · wider diffusion · FDA 2009.
The printed unit number on each vial means a different dose; always compare on a converted, Botox-equivalent basis.
Nabota and Dysport are both type-A botulinum toxins with the same mechanism of action, but they are not interchangeable units of the same medicine. The differences that actually drive a decision are the unit definition, how widely the product spreads, how fast it starts working and which treatment areas each tends to suit. Their written unit counts cannot be compared one-to-one: a "100-unit" amount is a very different dose in each product.
The direct answer
Nabota and Dysport both relax targeted muscles by temporarily blocking the nerve signal that triggers contraction. That shared mechanism is why they are used for the same kinds of concerns: frown lines, forehead lines, crow's feet, and jaw or shoulder slimming. The differences are in the product itself and how it behaves, not in a simple "which one is stronger" ranking.
The four differences that matter most when choosing:
- Units are not interchangeable. Nabota maps roughly 1:1 to onabotulinumtoxinA (Botox), while Dysport maps roughly 2.5:1 to 3:1. The same written number is not the same dose, so a price or dosage can only be compared after the clinician converts between brands.
- Spread (diffusion). Dysport is described as diffusing more widely, which suits larger muscle areas. Nabota is described as a lower-spread, high-purity product that suits precise, targeted areas.
- Onset. Dysport is often reported to take effect faster (roughly 1–2 days), while Nabota is usually described as taking around 2–5 days.
- Duration. Both are commonly described in the same range of about 3–6 months, with individual variation.
The honest conclusion is that neither product is universally "better." The right choice depends on the treatment area, the injector's familiarity with a specific brand, the converted dose and the budget. This article keeps the comparison neutral and verifiable rather than inventing a winner.
Same family, different products
Both Nabota and Dysport belong to the botulinum toxin type A class. They work the same way at a cellular level: they block the release of acetylcholine at the nerve–muscle junction, which relaxes the treated muscle and softens the lines or contours it creates. This is why the two products share the same broad safety profile and the same general expectations around temporary, repeatable results.
Where they diverge is in the molecule, the manufacturing lineage and the unit definition:
| Product attribute | Nabota | Dysport |
|---|---|---|
| Active substance | PrabotulinumtoxinA | AbobotulinumtoxinA |
| Origin / manufacturer | Daewoong, South Korea | Ipsen, Europe (distributed by Galderma in some markets) |
| Molecular structure | ~900 kDa complex; marketed with a HI-PURE™ high-purity process | 500–900 kDa range, associated with wider diffusion |
| Approximate unit ratio to Botox | ~1:1 | ~2.5:1–3:1 |
| Common vial sizes | 100 U, 200 U | 125 U, 300 U, 500 U |
| U.S. approval | FDA-approved 2019 as Jeuveau (prabotulinumtoxinA-xvfs) | FDA-approved 2009 (abobotulinumtoxinA) |
These facts describe the products accurately without ranking one as superior. The key point for a reader is that "type A" is a family, not a single interchangeable formula.
Why the units are not interchangeable
This is the most common source of confusion when comparing Nabota and Dysport, and it is the point that most ranking pages handle poorly. Different botulinum toxin brands define their units differently because each manufacturer's unit is standardised against its own product, not against a universal international dose.
In practice:
- Nabota is commonly described as roughly 1:1 with Botox. If a plan calls for 20 Botox units at a site, the converted Nabota amount is in a similar range, around 20 Nabota units.
- Dysport uses a different scale, commonly quoted at roughly 2.5:1 to 3:1 against Botox. A 20-unit Botox plan might convert to something like 50–60 Dysport units.
This is why a headline number can mislead. A Dysport vial of 300 units sounds larger than a Nabota vial of 100 units, but because the units are defined differently, the two numbers cannot be compared directly. A vial's usefulness depends on how many Botox-equivalent doses it contains, not on the printed unit count.
The practical rules:
- Never convert between brands yourself using a fixed multiplication. Conversion should be done by the treating clinician according to the current product labelling and clinical guidance.
- When comparing price, ask for the cost per converted, comparable treatment, not the price per "unit" on the label.
- Do not treat a "100-unit" Nabota treatment and a "100-unit" Dysport treatment as the same dose.
This article deliberately does not include an injection-dose table or per-treatment mixing numbers. Those belong to the treating professional, not to a comparison guide.
For a plain-language explanation of how botulinum units relate to millilitres, see the botulinum units vs mL guide.
Spread and where each is typically used
Diffusion is how far the product travels from the injection point into surrounding tissue. This difference translates directly into which areas each product tends to suit.
- Dysport is associated with wider diffusion. This can be an advantage when treating a larger, flatter muscle field, such as a broad forehead or the masseter (jaw) and shoulder or calf muscles used for slimming. The wider spread can cover more surface from fewer points.
- Nabota is associated with lower spread and precise placement. This can suit smaller, more defined areas where control matters, such as the glabellar (frown) lines and crow's feet, where excessive spread could affect nearby muscles that should stay active.
The description should not be read as "Nabota never spreads" or "Dysport always spreads too much." Spread is influenced by the dilution used, the injection technique and the anatomy, not only by the product. The brand's inherent diffusion tendency is one input the injector uses when planning a treatment, which is why treatment-area choice belongs with a qualified professional.
| Typical treatment area | Commonly discussed preference |
|---|---|
| Frown lines (glabellar), crow's feet | Precise, low-spread products such as Nabota are often favoured for control |
| Broad forehead, masseter / jaw slimming, shoulder / calf slimming | Wider-spread products such as Dysport are often favoured for coverage |
Again, this is a directional guide, not a rule that only one brand can be used in any single area. Many clinicians use either product across multiple areas with good results; their familiarity and the patient's anatomy often matter more than the brand.
Onset and duration
Onset is how quickly the relaxing effect becomes visible after injection.
- Dysport is frequently reported to act faster, with visible softening sometimes described within 1–2 days.
- Nabota is usually described as taking about 2–5 days for the effect to become apparent, with full results developing over one to two weeks.
Duration is how long the effect lasts. Both products are commonly described in a similar range of about 3–6 months, after which muscle activity gradually returns and a follow-up session is needed to maintain the result. Some individuals report longer or shorter durations depending on dose, muscle size, metabolism and how the body responds.
These figures are presented as ranges reported across clinic sources, not as guaranteed timelines. Individual results vary, and neither onset nor duration should be promised as a fixed number for any one patient.
Purity, brand origin and approvals
Nabota is manufactured by Daewoong, a South Korean pharmaceutical company, and is marketed with a HI-PURE™ high-purity production process and a ~900 kDa complex. It received U.S. FDA approval in 2019 under the name Jeuveau (prabotulinumtoxinA-xvfs), and holds several other market authorisations including Korean and European pathways. It is positioned as a modern Korean toxin with a high-purity emphasis.
Dysport is manufactured by Ipsen, a European company, with a longer market history and U.S. FDA approval from 2009. It is well established across Europe and other regions and is distributed by Galderma in certain markets.
Both products are legitimate, regulated type-A toxins with substantial clinical and commercial histories. The origin difference is a branding and availability question rather than a measure of safety or quality. Korean toxins such as Nabota are a well-established category; the relevant checks for any product are its current authorisation in the destination market and that it is obtained through a proper, verifiable channel.
Side effects and safety compared
Because Nabota and Dysport share the same mechanism, they share the same general side-effect profile. Common, usually temporary reactions include local tenderness, redness, swelling and bruising at the injection site, and mild headache. Effects related to the treatment itself, such as temporary heaviness in a treated area, depend more on dose, placement and technique than on the brand.
The wider diffusion associated with Dysport is sometimes discussed as increasing the chance of affecting an unintended nearby muscle when placement is not precise. This is a technique-and-dose consideration, not a defect in the product. Both products require an experienced injector who understands facial and muscle anatomy and converts doses correctly.
More serious but rare events, such as spread of toxin beyond the injection site, difficulty swallowing or breathing, muscle weakness, or an allergic reaction, are recognised risks for the entire botulinum toxin class. Anyone with an active infection at the treatment site, a neuromuscular condition, pregnancy or breastfeeding, or a history of reactions to a toxin product should raise this with the treating professional.
The key safety points:
- Never self-inject or obtain a toxin without a qualified prescriber.
- Confirm the product is obtained through a proper channel and is within date.
- Make sure the injector knows which product they are using, because unit conversion between brands is a real safety issue.
Read more on the shared safety considerations in the botulinum toxin safety guide.
Cost and buying considerations
Price comparisons between Nabota and Dysport are easy to misread because of the unit difference and because pricing is presented in several ways: per unit, per vial, per treatment area or per converted Botox-equivalent dose.
A few points that keep a price comparison honest:
- Per-unit price cannot be compared directly. Because Dysport uses roughly 2.5:1–3:1 the units of Botox, a lower "per-unit" price for Dysport does not automatically mean a cheaper treatment. The converted, comparable dose is what determines the real cost.
- Vial sizes differ. Nabota commonly comes in 100 U and 200 U vials, while Dysport comes in 125 U, 300 U and 500 U vials. A clinic's wastage and storage practice affects the effective price, so the vial that fits the treatment plan matters as much as the sticker price.
- Market availability differs. Nabota and other Korean toxins are widely available through aesthetic wholesalers, while Dysport's availability and pricing vary by region and distributor.
The right way to compare is to ask the clinic for the total price of a comparable treatment plan (same areas, same converted dose), not to compare a single printed number.
Nabota vs Dysport comparison table
A scannable summary of the differences discussed above.
| Dimension | Nabota | Dysport |
|---|---|---|
| Active substance | PrabotulinumtoxinA | AbobotulinumtoxinA |
| Manufacturer | Daewoong (South Korea) | Ipsen (Europe) |
| Unit ratio vs Botox | ~1:1 | ~2.5:1–3:1 |
| Diffusion | Lower spread, precise | Wider spread |
| Typical onset | ~2–5 days | ~1–2 days |
| Typical duration | ~3–6 months | ~3–6 months |
| Common vial sizes | 100 U, 200 U | 125 U, 300 U, 500 U |
| U.S. approval | 2019 (Jeuveau) | 2009 |
| Commonly favoured for | Frown lines, crow's feet, precise areas | Broad forehead, jaw / shoulder / calf slimming |
Which one is right for you
The decision should follow the treatment goal and the injector's assessment rather than a brand ranking. A useful way to think about it:
- If the goal is precise work on a small, defined area such as frown lines or crow's feet, a low-spread, high-purity product like Nabota is often a natural fit.
- If the goal is broad coverage of a larger muscle area, such as the forehead, jaw, shoulders or calves, a wider-spread product like Dysport is often a natural fit.
- If speed of onset is the priority, Dysport's faster reported onset may be relevant.
- If Korean-brand availability or a high-purity positioning matters to the buyer, Nabota and the wider Korean toxin range are the direction.
Ultimately, the best product is the one your injector is experienced with, dosed correctly for your anatomy and obtained through a proper channel. The brand is one input among several, not the whole decision.
Frequently asked questions
Is Nabota better than Dysport?
No product is categorically better. They share a mechanism but differ in units, spread and onset. Nabota suits precise areas and is a high-purity Korean brand; Dysport spreads more widely and often acts faster. The right choice depends on the treatment area, the converted dose and the injector's experience.
Are Nabota and Dysport units the same?
No. Nabota is roughly 1:1 with Botox, while Dysport is roughly 2.5:1–3:1. The same written unit number is not the same dose, so doses must be converted by the clinician and prices compared on a converted, comparable basis.
Does Dysport work faster than Nabota?
Dysport is often reported to take effect faster, sometimes within 1–2 days, while Nabota is usually described as taking about 2–5 days. Both should be described as ranges rather than fixed promises.
How long do Nabota and Dysport last?
Both are commonly described as lasting about 3–6 months, with individual variation depending on dose, muscle size and metabolism. A follow-up session is typically needed to maintain results.
Which one is cheaper?
Price cannot be compared by the printed unit or vial number, because the units are defined differently. A lower per-unit price for Dysport does not automatically mean a cheaper treatment. Compare the total price of a converted, comparable treatment plan.
Which one is better for the forehead?
Dysport's wider spread is often used for broad forehead coverage, while a precise product like Nabota is often preferred for smaller, defined areas. The injector's plan and familiarity matter more than a fixed rule.
Which one is better for jaw or masseter slimming?
Dysport's wider diffusion is often discussed for larger muscles like the masseter, shoulders and calves. Either product can be used successfully; the dose conversion and injector experience are the deciding factors.
Which one is better for frown lines or crow's feet?
Precise, lower-spread products such as Nabota are often favoured for frown lines and crow's feet, where control over nearby muscles matters. Again, this is a directional preference, not a restriction.
Is Nabota a "Korean Botox"?
Nabota is a Korean type-A botulinum toxin with a high-purity positioning, and it was FDA-approved in the U.S. under the name Jeuveau. The "Korean Botox" shorthand refers to its origin and family, not to an identical formula to Botox.
Can I convert the dose myself?
No. Conversion between brands should be performed by the treating clinician using current product labelling and clinical guidance. This article intentionally does not provide an injection-dose table or any step-by-step mixing instructions.
Where to buy Nabota and Korean toxins
MJS supplies Korean botulinum toxins including Nabota, alongside other Korean aesthetic products. Dysport is a European product and is not part of the MJS Korean-toxin catalogue; this page compares the two honestly and routes readers to the products MJS does carry.
- Nabota 100 U product page
- Nabota 200 U product page
- Nabota vs Botox comparison
- Botulinum units vs mL guide
- Botulinum toxin safety guide
- Contact MJS
MJS is presented here as a distributor and product channel, not as the manufacturer of Nabota or as a clinical treatment provider. Product availability, pricing and local regulatory status should be confirmed directly.
Evidence sources and what they support
- Nabota vs Botox comparison (MJS) — internal cluster page for the same product family.
- Botulinum units vs mL guide (MJS) — plain-language explanation of unit and millilitre differences.
- Botulinum toxin safety guide (MJS) — shared safety considerations for the toxin class.
- Daewoong Nabota manufacturer product page — manufacturer-level product identity and Korean-market presentation.
- Ipsen Dysport manufacturer product page — manufacturer-level product identity and European-market presentation.
- U.S. FDA approval record: Jeuveau (prabotulinumtoxinA-xvfs), 2019 — U.S. regulatory identity of Nabota under the name Jeuveau.
- U.S. FDA approval record: Dysport (abobotulinumtoxinA), 2009 — U.S. regulatory identity of Dysport.
- Walker & Dayan systematic review: botulinum toxin clinical pharmacology and units — academic background on unit definition, dose conversion and diffusion differences between botulinum toxin brands.
- PubMed Central PMC6039073: Asian botulinum toxin type A formulation comparison — comparative molecular and purity data informing the Nabota vs Dysport unit-ratio discussion.
Note: onset and duration figures are presented as ranges reported across clinic and manufacturer sources, not as guaranteed timelines. Product facts were verified against publicly available sources on 2 September 2026.
